Artwork

Contenido proporcionado por Johns Hopkins Malaria Research Institute and Johns Hopkins Bloomberg School of Public Health. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Johns Hopkins Malaria Research Institute and Johns Hopkins Bloomberg School of Public Health o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Player FM : aplicación de podcast
¡Desconecta con la aplicación Player FM !

Turning Drugs Into Vaccines to Offer Longer-Term Protection Against Malaria

1:08
 
Compartir
 

Manage episode 386124461 series 3531530
Contenido proporcionado por Johns Hopkins Malaria Research Institute and Johns Hopkins Bloomberg School of Public Health. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Johns Hopkins Malaria Research Institute and Johns Hopkins Bloomberg School of Public Health o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

How ‘chemical vaccines’ could offer long-term protection against malaria in endemic areas, and combat the problems of dosing and drug resistance.

Transcript

Drugs used to prevent and treat malaria are vital tools in the malaria toolkit – but they aren’t perfect. When used to prevent malaria, people must remember to take them regularly, or they won’t be as effective. And when they’re used to treat the disease, the sheer scale of infection – with billions of parasites in the body – makes it likely that some of those parasites will be drug-resistant, leading to treatment failure. But, when you formulate the drugs differently, as nano-particles in a water-based solution, and inject them, like a vaccine, those same drugs can offer effective, long-lasting protection against the disease. This so-called ‘chemical vaccine’, based on the antimalarial drug atovaquone, has been shown in mice to effectively stop the infection and subsequently, the onward transmission of the parasites to mosquitoes. The long-term hope is that a single dose of the ‘chemical vaccine’ could offer long-term protection against malaria in endemic areas, and help combat the problems of dosing and drug resistance.

Source

Clinically relevant atovaquone-resistant human malaria parasites fail to transmit by mosquito

About The Podcast

The Johns Hopkins Malaria Minute podcast is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and to share it with the global community.

  continue reading

67 episodios

Artwork
iconCompartir
 
Manage episode 386124461 series 3531530
Contenido proporcionado por Johns Hopkins Malaria Research Institute and Johns Hopkins Bloomberg School of Public Health. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Johns Hopkins Malaria Research Institute and Johns Hopkins Bloomberg School of Public Health o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

How ‘chemical vaccines’ could offer long-term protection against malaria in endemic areas, and combat the problems of dosing and drug resistance.

Transcript

Drugs used to prevent and treat malaria are vital tools in the malaria toolkit – but they aren’t perfect. When used to prevent malaria, people must remember to take them regularly, or they won’t be as effective. And when they’re used to treat the disease, the sheer scale of infection – with billions of parasites in the body – makes it likely that some of those parasites will be drug-resistant, leading to treatment failure. But, when you formulate the drugs differently, as nano-particles in a water-based solution, and inject them, like a vaccine, those same drugs can offer effective, long-lasting protection against the disease. This so-called ‘chemical vaccine’, based on the antimalarial drug atovaquone, has been shown in mice to effectively stop the infection and subsequently, the onward transmission of the parasites to mosquitoes. The long-term hope is that a single dose of the ‘chemical vaccine’ could offer long-term protection against malaria in endemic areas, and help combat the problems of dosing and drug resistance.

Source

Clinically relevant atovaquone-resistant human malaria parasites fail to transmit by mosquito

About The Podcast

The Johns Hopkins Malaria Minute podcast is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and to share it with the global community.

  continue reading

67 episodios

Todos los episodios

×
 
Loading …

Bienvenido a Player FM!

Player FM está escaneando la web en busca de podcasts de alta calidad para que los disfrutes en este momento. Es la mejor aplicación de podcast y funciona en Android, iPhone y la web. Regístrate para sincronizar suscripciones a través de dispositivos.

 

Guia de referencia rapida